
|Articles|August 1, 2003
Long-term Safety and Tolerability Experience with TNF Inhibitors
Author(s)Steven Feldman, MD, PhD
The class of agents known as TNF inhibitors shares some common safety issues, but the safety profiles of specific agents vary due to differing characteristics and mechanisms. Comparing safety data of these drugs is, of course, complicated by differences in patient populations and experiences.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














